Most people who test positive for ANCAs — the self-reactive antibodies that drive most ANCA-associated vasculitis (AAV) cases —…
Articles by Margarida Maia, PhD
Tavneos (avacopan) can control ANCA-associated vasculitis (AAV) just about as well as standard glucocorticoids but causes fewer side…
In severe ANCA-associated vasculitis (AAV), rituximab may be superior to cyclophosphamide at helping people survive beyond 10 years…
An increase in blood levels of a self-reactive antibody called MPO-ANCA predicted the return of ANCA-associated vasculitis (AAV) symptoms…
About half of the patients who began dialysis due to kidney disease from ANCA-associated vasculitis (AAV) could stop it…
A greater disease burden and poorer physical quality of life were found for people with eosinophilic granulomatosis with polyangiitis (EGPA)…
In ANCA-associated vasculitis (AAV), about 1 in every 4 patients with glomerulonephritis, a type of kidney inflammation, have C3…
Use of the experimental therapy BDB-001 helps adults with ANCA-associated vasculitis (AAV) achieve at least partial disease remission, while…
Measuring circulating microRNAs — short RNA molecules that ultimately suppress gene activity — could offer doctors a less invasive way…
Treatment with the immunosuppressants cyclophosphamide, azathioprine, or rituximab after ANCA-associated vasculitis (AAV) patients have experienced a brain bleed, or…